ALK rearrangement in renal cell carcinoma represents a rare molecular subtype in these entities.Only a few cases have been reported to receive ALK-directed therapy in a later-line metastatic setting.We report the case of a 23-year-old male patient with pulmonary metastatic RCC harboring an ALK rearrangement.The initial histological sample obtained from a kidney biopsy revealed a VCL-ALK fusion.Subsequently, the patient received first-line therapy with alectinib, a highly selective ALK inhibitor.Following nearcomplete remission of multiple pulmonary nodules, as well as a partial response of the retroperitoneal lymph nodes and the primary tumor, a cytoreductive nephrectomy was performed.The patient remains on ALK-directed maintenance therapy and has achieved a complete remission.To the best of our knowledge, this is the first published case worldwide using an ALK inhibitor first-line in metastatic RCC.